Seeking Alpha

Ironwood Pharmaceuticals (IRWD) sinks 13.3% premarket after saying sales of Linzess — the...

Ironwood Pharmaceuticals (IRWD) sinks 13.3% premarket after saying sales of Linzess — the IBS drug the company markets with Forest Labs (FRX) — were $4.5M for Q1 versus expectations of $11-13M. Credit Suisse and Wedbush previously said early evidence suggested demand for the drug was strong. Irina Rivkind at Cantor says Synergy's (SGYP) investigational candidate plecanatide has the potential to achieve revenue parity with Linzess.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs